Xencor Priced, Nasdaq: XNCR
Biotech developing antibodies for severe autoimmune/allergic diseases and cancer.
Industry: Health Care
First Day Return: +51.6%
XNCR
Biotech developing antibodies for severe autoimmune/allergic diseases and cancer.
| IPO Data | |
|---|---|
| IPO Date | 12/02/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Monrovia, CA, United States |
| Founded | 1997 |
| Employees at IPO | 31 |
| Website www.xencor.com | |
IPO News for Xencor
Xencor (XNCR) Performance
